# Bob Saunders

> Bob Saunders is a pre-seed investor at OCA Ventures backing Health Care and Biotechnology. See 14 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [OCA Ventures](https://shizune.co/investors/profile/oca-ventures)
- Location: Louisville, United States
- Total investments: 14
- Last investment: Aug 2022
- Lead investor: 57%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/bob-saunders-84a3993

Bob Saunders is a pre-seed investor at OCA Ventures in Louisville focused on Health Care and Biotechnology. Bob Saunders is general partner at OCA Ventures

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 10 | 71% |
| Biotechnology | 4 | 29% |
| Medical | 3 | 21% |
| Wellness | 2 | 14% |
| Enterprise Software | 2 | 14% |

26 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 5 | 36% |
| Seed | 4 | 29% |
| Series A | 4 | 29% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biotia | Biotia is a health tech company spun out of Cornell Tech leveraging next-generation sequencing and artificial intelligence for rapid and precise infectious disease discovery. Their software and laboratory technology enable clinicians and researchers to guide patient treatment and improve health outcomes. | $8M | Series A | Aug 23, 2022 |  |
| AMOpportunities | AMOpportunities connects international medical students and graduates with U.S. physicians and institutions for clinical experiences. The company's platform offers individuals the opportunity to explore and apply for clinical experiences at 200+ clinical sites across 70+ medical specialties and subspecialties. AMO provides exceptionalsupport services such as visa and housing assistance.It was founded in 2013 and based in Chicago, Illinois. | $7.4M | Series A | Dec 16, 2021 |  |
| Nexosome Oncology | Nexosome Oncology focus on the applications of exosome-based diagnostics in the cancer field. | $3.7M | Seed | Nov 22, 2021 |  |
| Votive Health | Votive Health is a technology-enabled network manager delivering complex care at home for people facing serious illnesses. Founded in 2020, the company is based in San Luis Obispo, California, United States. | $2.5M | Seed | Apr 28, 2021 |  |
| nQ Medical | nQ Medical is a digital therapeutics company addressing neurocognitive and neuromotor disorder via 24/7, passive data collection via personal devices. It is a frictionless, non-invasive, early detection, remote disease progression monitoring, and therapeutic measurement modality. nQ uses an artificial intelligence company to developcomputational biomarkers that have been proven in five years of clinical trials to substantially change the way disease is managed for a wide range of neuromotor and neurocognitive disorders (Alzhemer's, Parkinson's, Multiple Sclerosis, ALS, concussion, et al. The platfomr focuses on analysis of user interaction with common electronic devices to capture functional decline related to neurodegenerative disorders. The fine control of typing and touch screen kinematics together with the frequent use of electronic devices allows for precise monitoring of small changes in neurodegeneration that frequently go unnoticed by clinicians. nQ allows for early detection of disease, 24/7, passive, at home, remote monitoring of disease progression and the measurement of impact of therapy at a fraction of the cost of current gold standards. There is no required task. Just use your device as your would normally use it. Of note, as one of the company's medical advisors, Zoltan Mari, MD, of the Cleveland Clinic, so aptly quoted: "As important as it is to fund novel compounds for treating diseases, it is also important to set the stage for maximum impact when those compounds are discovered and approved for use. It is impossible to find a cure without early detection. That's why drug candidates fail. When the FDA puts its stamp on the first disease modifying drugs, such early detection technologies will be instantly necessary." He goes on to state further: "We also need a disease progression marker. Nothing so far has managed to do very well (while being profoundly expensive). Much of our research and clinical interest is turning toward disease progression. All efforts should focus on readying and perfecting early detection tools and building effective, reliable, inexpensive ways of tracking disease and the impact of therapy over time.” nQ is that early detection, disease progression computational biomarker. | $1.6M | Seed | Nov 27, 2018 |  |
| PatientWisdom, Inc. | PatientWisdom, Inc. developed a SaaS digital health platform that transforms the experience and delivery of care by listening to the people involved, individually and at scale. The offers three powerful solutions: PatientWisdom makes it easy to understand what matters to patients ahead of clinical encounters so providers can do better withouttaking longer; ProviderWisdom obtains real-world insights from clinicians and staff to create more responsive ecosystems that enhance engagement, address burnout and streamline care; CommunityWisdom produces a deep view of the community to give health organizations clear lines-of-sight for developing or partnering with programs people will use. The Tech Tribune named PatientWisdom, Inc. one of the Best Tech Startups in 2018 and 2019, and PatientWisdom was named “Most-Patient Centered” and an Audience Favorite at the Health Tech StandOut! Competition during the 2018 Connected Health Conference. | $1M | Series A | Jul 31, 2018 |  |
| DesiCorp | DesiCorp extends blood shelf-life by drying it to powder that can be stored for longer than 42 days without refrigeration for emergencies. |  | Pre-Seed | Jul 24, 2018 |  |
| Sentry Health | SentryHealth is leading the charge in employee health and wellbeing. Our integrated health management solution is the perfect combination of technology and personalized support from caring medical professionals. Powered by AI, we analyze data from multiple sources to develop unique Intelligent Profiles complete with personalized recommendations.Pairing these profiles with smart technology and Registered Nurse Advocates, we engage with each employee to ensure they receive the right care at the right time. The result is better participation, higher satisfaction, greater outcomes, and lower costs. | $5.3M | Series A | Jul 10, 2018 |  |
| Digital Health Solutions | Digital Health Solutions software help physicians identify pediatric patients' problems earlier and better document the quality of care. |  | Pre-Seed | Aug 10, 2017 |  |
| Epikardis Medical | Epikardis Medical LLC is a medical company focused on identifying ineffective methods and products in the medical field and developing cost-efficient replacements with clear, proven benefits. |  | Pre-Seed | Jul 27, 2016 |  |

10 of 14 investments shown.

## Co-investors
- [Keyhorse Capital](https://shizune.co/investors/profile/keyhorse) — VC Fund, 2 deals together
- [Lunsford Capital](https://shizune.co/investors/profile/lunsford-capital) — VC Fund, 2 deals together
- [Keyhorse Capital (KSTC)](https://shizune.co/investors/profile/mammothview) — VC Fund, 2 deals together
- [Mayo Clinic Platform](https://shizune.co/investors/profile/mayo-clinic-platform) — VC Fund, 2 deals together
- [Betaworks](https://shizune.co/investors/profile/betaworks) — VC Fund, 1 deal together
- [Chicago Early Growth Ventures (CEGV)](https://shizune.co/investors/profile/chicago-early-growth-ventures-cegv) — VC Fund, 1 deal together

## About OCA Ventures

VC Fund · Chicago, United States

We're an early stage venture capital firm focused on equity investments in companies with dramatic growth potential, primarily in technology and highly-scalable services businesses. Our focus investment areas are digital health, fintech, consumer software, and enterprise software.

5 contacts available at OCA Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Bob Saunders | General Partner | https://shizune.co/investors/profile/bob-saunders |
| Ian Drury | Venture Partner | https://shizune.co/investors/profile/ian-drury |
| Jim Dugan | CEO, Co-Founder, and Founding Managing Partner | https://shizune.co/investors/profile/james-dugan |
| John Dugan | Chairman Emeritus & Co-Founder | https://shizune.co/investors/profile/john-dugan |
| Dana Sun | Senior Associate | https://shizune.co/investors/profile/dana-sun |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

## FAQ

### What does Bob Saunders invest in?

Bob Saunders invests primarily in Health Care, Biotechnology and Medical startups, most often at Pre-Seed and Seed stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Bob Saunders last invest?

The most recent investment recorded for Bob Saunders closed in Aug 2022. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co